TP53 and cancer: As depletion of RUNX2 improved adriamycin- and GEM sensitivity of U2OS cells and AsPC-1 cells, respectively,37, 38, 39 it is likely that knockdown of RUNX2 has a vital role in the improvement of chemo-sensitivity of cancer cells regardless of their p53 status.